-+ 0.00%
-+ 0.00%
-+ 0.00%

Turn Therapeutics Q2 FY26 net loss widens to USD 5.85 million

PUBT·08/12/2026 20:30:40
Listen to the news
Turn Therapeutics Q2 FY26 net loss widens to USD 5.85 million
  • Turn Therapeutics posted a Q2 2026 net loss of $5.85 million, widening from $1.24 million a year earlier.
  • Operating loss widened to $1.63 million; R&D spending rose to $475,064 from $62,678 on higher Phase 2 activity.
  • Cash and cash equivalents climbed to $10.3 million at June 30, 2026; runway projected into Q3 2027.
  • Interim Phase 2 GX-03 data review prompted Stage 2 expansion to about 120-135 atopic dermatitis patients; enrollment still targeted by end-2026.
  • Stephen M. Hahn joined as executive clinical and regulatory lead; peer-reviewed preclinical GX-03 data published in Journal of Dermatological Treatment.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260812643155) on August 12, 2026, and is solely responsible for the information contained therein.